

CS Pharmaceuticals announces strategic cooperation agreement with Medical Insight to jointly built a digital platform for rare diseases

London, England, 12 Dec 2021, CS Pharmaceuticals Ltd. (CSP), a British speciality pharmaceutical company focused on first- and best-in-class speciality therapeutics and treatments for rare diseases in China, are pleased to announce the signing of a strategic cooperation agreement with Shanghai Medical Insight Technology CO., LTD (Medical Insight) to jointly built a digital platform for rare diseases

“We are delighted to have signed a cooperation agreement with Medical Insight. CSP was established in 2021, to introduce drugs in the field of rare diseases and specialised care to China. By introducing these innovative products to China, our goal is to meet the unmet medical needs and benefit patients. In China, the awareness rate and diagnosis rate of some rare diseases are still relatively low, and we hope that through our combined efforts, we can improve this situation. By helping patients better understand a rare disease and improve treatment we aim to improve the patient's quality of life. It is hoped that by introducing rare disease products to China and strategically partnering with China Medical Insight, we can truly make a difference to patients' lives”, said Darren Mercer CEO of CSP.

Mr. Luan Qijia, General Manager of Medical Insight said: "Medical Insight is a leading medical consulting company in China, we firmly believe that medicine drives business growth, and we also believe that only innovative and integrated medical and marketing solutions can bring more value. At present, we have become the preferred supplier or even innovative supplier of many leading foreign pharmaceutical companies, providing customers with comprehensive medical services throughout the life cycle of products. We are very honoured to be a partner of CSP and look forward to carrying out innovative cooperation projects with CSP to benefit more patients with rare diseases in China."

About CS Pharmaceuticals

CS Pharmaceuticals (CSP) is a British multinational pharmaceutical company focused on licensing Chinese commercialisation rights to Western rare disease and speciality medicines. The company, with its headquarters in London and offices in Beijing and Shanghai, offers dedicated regulatory, market access, medical and commercial expertise, in addition to international-standard compliance and legal capabilities. The team has an impressive track record of success in China, providing partners with significant experience in this fast-growing market. With its dedicated commercialisation platform, CSP is rapidly becoming a 'go-to' trusted licensing partner, expanding its portfolio of innovative rare disease and ophthalmology assets while making business easier for companies wishing to develop and commercialize their products in China.

www.cspharmaceuticals.com

Contacts

CS Pharmaceuticals
Darren Mercer, Chief Executive Officer

Tel: +44 (0) 2037 534691



Mr. Luan Qijia
General Manager
Medical Insight

Dr Elaine Nie
VP Regulatory and Clinical
CS Pharmaceuticals



Signing Ceremony